Thursday’s Focus: (Nasdaq: GTBP) Coverage Drops Early Tomorrow—Here’s Why

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored GT Biopharma, Inc. (Nasdaq: GTBP) Gets The Krypton Street Spotlight Tomorrow —Thursday, May 14, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. (GTBP) Coverage Will Be Starting Early Make Room For (GTBP) On Tomorrow’s Watchlist … May 13, 2026 Thursday’s Focus | (Nasdaq: GTBP) Coverage Drops Early Tomorrow—Here’s Why Dear Reader, Krypton Street is tracking a clinical-stage biotech below $0.50 that just made an approximate 59% move in under a week — and despite the recent momentum, the name is still flying well below the radar. GT Biopharma, Inc. (Nasdaq: GTBP) is developing a proprietary natural killer (NK) cell engager platform that has already demonstrated proof of concept in cancer patients, while also preparing to advance a second clinical program targeting multiple solid tumor types in mid-2026. Between two active clinical-stage assets, funding guidance extending into Q4 2026, and a pipeline spanning oncology and autoimmune disease, (GTBP) quickly moved toward the top of the Krypton Street watchlist heading into tomorrow’s session— Thursday morning, May 14, 2026. What makes this setup stand out is the combination of near-term clinical timelines, recent momentum, and a platform aimed at several difficult-to-treat disease areas. For a company still flying this far under the radar, (GTBP) gives readers plenty to pay attention to as Thursday’s session approaches. How GT Biopharma, Inc. (Nasdaq: GTBP) Targets Cancer Differently GT Biopharma, Inc. (Nasdaq: GTBP) is a San Francisco-based clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary TriKE® (Tri-Specific NK Cell Engager) platform. Unlike CAR-T therapies — which require cells to be harvested and modified outside the body — (GTBP)’s approach is designed to harness and enhance the cancer-killing ability of a patient's own NK cells directly in vivo, without removing or modifying those cells prior to treatment. The company holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using the TriKE® technology. The TriKE® platform is built around a tri-specific molecule with three functional domains: an anti-CD16 nanobody that binds and activates NK cells via antibody-dependent cellular cytotoxicity (ADCC), an IL-15 crosslinker that promotes NK cell expansion and persistence at the tumor site, and an anti-tumor associated antigen (TAA) binding domain that directs NK cells to specific cancer markers. This modular architecture allows (GTBP) to efficiently adapt the platform across different tumor targets — a key design advantage. (GTBP)’s active pipeline includes three named TriKE® candidates: GTB-3650, a second-generation camelid nanobody TriKE® currently in a Phase 1 dose escalation trial for relapsed or refractory (r/r) CD33-expressing hematologic malignancies including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS); GTB-5550, a B7-H3-targeted TriKE® that received FDA IND clearance in February 2026 with a Phase 1 basket trial planned for mid-2026; and GTB-7550, a CD19-targeted candidate in preclinical development for lupus and other autoimmune disorders. The $136B Immunotherapy Backdrop Behind (GTBP) The broader cancer immunotherapy market was valued at approximately $136B in 2025 and is projected to reach roughly $367B by 2035, growing at a compound annual growth rate (CAGR) of approximately 10.4%. Within that broader landscape, the NK cell therapeutics segment is expanding even faster — valued at $3.2B in 2024 and forecast to reach $8.6B by 2033. (GTBP)’s GTB-5550 program targets a portion of the estimated $362B global solid tumor market, according to the company's January 2026 IND announcement. The upcoming Phase 1 basket trial covers up to seven potential metastatic cancer cohorts: castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. The TriKE® mechanism is also designed to avoid the most severe side effects associated with competing modalities. CAR-T therapies are widely associated with cytokine release syndrome (CRS) and neurological complications stemming from T-cell hyperactivation. GTBP's approach selectively activates NK cells rather than T cells, potentially offering a more tolerable safety profile — an important distinction in the immunotherapy landscape. Big pharmaceutical companies have taken notice: Sanofi and Gilead both completed significant NK cell engager deals valued at over $1B in milestone and upfront payments, according to GT Biopharma's March 2026 corporate presentation. Proof of Concept in the Clinic — and a Second-Generation Upgrade (GTBP)’s clinical foundation is not speculative — the company's first-generation TriKE®, GTB-3550, completed a Phase 1 study in AML and MDS patients and demonstrated reproducible NK cell proliferation, activation, and persistence across all patients and all dose levels, with minimal clinically significant toxicity. In select patients, GTB-3550 showed reductions in CD33+ bone marrow blast levels: 33.3% in one patient, 61.7% in another, 63.6% in a third, and 50% in a fourth — encouraging early signals for a first-in-class modality at lower dose levels. Building on those results, (GTBP)’s second-generation candidate GTB-3650 incorporates camelid nanobody technology for improved potency, enhanced binding affinity, commercial manufacturing capabilities through Cytovance, and full proprietary ownership by GT Biopharma. The Phase 1 dose escalation trial (NCT06594445) is actively enrolling, with Cohort 5 dosing (25 µg/kg/day) expected to begin in Q2 2026 and the next data update anticipated in Q3 2026 — covering longer-term follow-up for patients in Cohorts 1 through 3, plus initial observations from Cohorts 4 and 5. Financial Position: Funded Into Q4 2026 According to (GTBP)’s full year 2025 financial results, the company held cash and cash equivalents of approximately $7M as of December 31, 2025, and an unaudited proforma cash balance of approximately $9M as of January 31, 2026. Management anticipates this runway to fund operations through Q4 2026 — spanning both the continued enrollment of the GTB-3650 Phase 1 trial and the planned mid-2026 initiation of the GTB-5550 basket trial. Full year 2025 R&D expenses came in at approximately $3.5M, down from $5.8M in 2024, primarily reflecting reduced production and material costs as the company sharpened its development focus. 7 Reasons We’re Watching (GTBP) Tomorrow Morning —Thursday, May 14, 2026 … 1. Flying Under the Radar: With a market cap below $12M, (GTBP) sits in a smaller valuation range than many clinical-stage biotech names, which could suggest a higher-potential for growth. 2. Recent Momentum: After an approximate 59% move in under a week, (GTBP) is now at the top of our watchlist. 3. Active Trial: The Phase 1 dose escalation study for GTB-3650 is actively enrolling, giving (GTBP) a live clinical timeline. 4. Q3 Update: A GTB-3650 data update is anticipated in Q3 2026, giving (GTBP) a defined upcoming milestone. 5. Platform Design: The TriKE® platform allows (GTBP) to adapt its NK cell engager approach across different tumor targets. 6. Cash Runway: Management expects current funding to support (GTBP) operations through Q4 2026. 7. FDA-Cleared Path: With GTB-5550 cleared by FDA for a planned mid-2026 Phase 1 basket study, (GTBP) has another clinical program approaching. Make Room For (GTBP) On Tomorrow’s Watchlist … Between the recent momentum, active clinical enrollment, upcoming Q3 2026 data timeline, and a second FDA-cleared program preparing to enter the clinic, (GTBP) is beginning to draw attention at a time when several important developments appear to be lining up simultaneously. The company’s TriKE® platform also gives (GTBP) exposure across multiple disease areas, while current funding guidance through Q4 2026 provides visibility into the next stage of clinical execution. For a biotech still operating with a market cap below $12M, the setup is difficult to ignore. (GTBP) will be front and center for us tomorrow morning—Thursday, May 14, 2026. Take a few minutes to look it over tonight. Keep an eye out for our morning update — it may hit sooner than you think. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter   KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 05/13/2026 and ending on 05/14/2026 to publicly disseminate information about (GTBP:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the one hundred fifty thousand USD funds that TD Media LLC received from GT Biopharma Inc., the issuer of (GTBP:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (GTBP:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/gtbp-7EFK4/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by alex@kryptonstreet.com